The grant, matched by Frequency, will fund research to optimize the company's Progenitor Cell Activation Regeneration platform, which will explore a small molecule approach to convert intestinal stem cells into cells capable of insulin secretion for the treatment of T1D.
This research agreement aims to achieve one of JDRF's key therapeutic goals, exploring beta cell replacement in an effort to achieve insulin independence in people with T1D.
The grant will fund Frequency's research into its PCA Regeneration platform's ability to stimulate gastrointestinal stem cells to differentiate into insulin-producing beta cells, in an effort to discover and develop new therapies for type 1 diabetes.
The terms of the grant agreement were not disclosed.
Frequency Therapeutics develops small molecule drugs to stimulate cells in the body to reverse biological deficits and restore healthy tissue.
Through the transitory activation of these cells, the company enables disease modification without the complexity of genetic engineering. Its breakthrough therapy uses a proprietary combination of small-molecule drugs that induce dormant progenitor cells to multiply and create new cells.
Renalytix expands US clinical footprint with three kidneyintelX.dkd integrations
GSK wins European Commission approval for Shingrix prefilled syringe
Abbott launches Libre Assist for in-the-moment food decisions
RedHill advances RHB-102 across GI indications
FDA grants priority review for Sanofi's Tzield in young children with stage 2 type 1 diabetes
Samsung Bioepis begins direct commercialisation of BYOOVIZ in Europe
Diamyd Medical agrees accelerated efficacy readout in ongoing Phase 3 type 1 diabetes trial
Clywedog Therapeutics activates all clinical centres and patient dosing in balomenib Phase 1b study
Qlife's Egoo Health platform selected for major AI-driven diabetes and MASLD project in China
ALR Technologies announces GluCurve Pet CGM relaunch in Canada
Gan & Lee Pharmaceuticals launches third phase 3 trial of once-monthly bofanglutide
Novo Nordisk reports strong phase 2 results for amycretin in type 2 diabetes
Innovent Biologics reports primary and all key secondary endpoints met in mazdutide Phase 3 trial
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Adocia files patent for long-acting peptide platform AdoXLong and updates on BioChaperone studies